Alpha Synuclein drugs in development by Therapy Areas, Indications, Stages, MoA, RoA, Molecule Type, and Key Players, 2023

The report also covers products from therapy areas such as Central Nervous System, Metabolic Disorders, and Cardiovascular which include the indications Parkinson’s Disease, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), Type 2 Diabetes, Amyloidosis, Myocardial Infarction, and Ischemia. It also reviews key players involved in Alpha Synuclein targeted therapeutics development with respective active and dormant or discontinued products.

The Alpha Synuclein pipeline targets constitutes close to 82 molecules. Out of which, approximately 71 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, Discovery, and Unknown stages are 1, 10, 16, 2, 37, 21, and 1 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 9, and 2 molecule.

Alpha Synuclein overview

Alpha-synuclein is a protein normally found in cells all over the body. It is one of the key players in Parkinson’s. In Parkinson’s it forms clumps inside the specific nerve cells that produce the chemical dopamine. It is involved in the regulation of dopamine release and transport. It induces fibrillization of microtubule-associated protein tau. It reduces neuronal responsiveness to various apoptotic stimuli, leading to decreased caspase-3 activation.

For a complete picture of Alpha Synuclein’s drug pipeline, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.